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Abstract
Background: Previous studies demonstrated the EGF-targeted phagemid particles carrying siRNA
against Akt could be expressed efficiently in the presence of hydroxycamptothecin (HCPT).
However, no significant cell growth inhibition was obtained. This study was to further investigate
whether the EGF-targeted phagemid particles carrying siRNA would be a promising tool for anti-
cancer siRNA delivery.
Results: We found that pSi4.1-siFAK phagemid particles could significantly inhibit the expression
of focal adhesion kinase in the HCPT-treated cells. Moreover, we also observed that the particles
could potently suppress cell growth and cell invasion.
Conclusion: These results indicated that EGF-targeted phagemid particles might be a promising
tool for anti-cancer siRNA delivery in the presence of HCPT.
Background
Small interfering RNA (siRNA) molecules are capable of
interrupting the translation of a specific protein by induc-
ing post-transcriptional gene silencing. It is a promising
method for silencing therapeutic target genes. A variety of
delivery systems are proposed for the delivery of siRNA
into cells in vitro and in vivo. Since phage-based vectors do
not exhibit natural tropism towards mammalian cells and
can be genetically modified for specific applications,
modified phage-based vectors are an attractive alternative
strategy for gene delivery. They have been successfully
modified to deliver genes to target cells by the effective use
of targeting ligands such as growth factors, antibodies,
and viral capsid proteins [1-7]. To increase the density of
ligand display on the phages, an epidermal growth factor
(EGF)-modified helper phage genome M13EGFKO7CT
was established, which could produce EGF-targeted
phagemid particles [8]. The phagemid particles could
deliver reporter genes into target cells; however, the effi-
ciency of delivery was limited [8]. A topoisomerase I
inhibitor such as camptothecin or hydroxycamptothecin
(HCPT) could substantially enhance the transduction of
the phagemid gene delivery particles [1,9]. The recent
studies showed that the cell-targeted phagemid particles
could efficiently deliver siRNA against Akt into cell in the
presence of HCPT [10]. But, no significant growth inhibi-
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tion was observed. Thus, to be an effective anti-cancer
siRNA delivery vector, more studies should be performed,
such as carrying siRNA against other oncogenes.
Focal adhesion kinase (FAK), a non-receptor tyrosine
kinase, has been implicated in several cellular processes
such as proliferation, apoptosis, motility, and invasion.
Increased expression of FAK has been found in various
malignant tumors, including tumors derived from the
lungs, breasts, head and neck, and ovaries [11-14]. There-
fore, FAK is recognized as an important therapeutic target
in the treatment of cancer. Delivery of siFAK by lipo-
fectamine could significantly block the expression of FAK
and trigger cell death and block cell migration [15]. But,
the siFAK could not be delivered to target cells. To further
investigate whether the EGF-targeted phagemid particles
in combination with RNA interference (RNAi) would rep-
resent an effective therapeutic approach, we used
phagemid particles carrying siRNA against FAK to infect
H1299 cells and examined the therapeutic potential of
this approach.
Results and Discussion
Previous studies showed that the cell-targeted phagemid
particles were efficient siRNA delivery vectors in the pres-
ence of HCPT and they could efficiently deliver siRNA
against Akt into targeted cells in the presence of HCPT
[10]. But, no significant growth inhibition was observed.
Thus, to be an effective anti-cancer siRNA delivery vector,
more studies should be performed, such as carrying siRNA
against other oncogenes. In this study, we made
phagemid particles carrying siRNA against FAK to infect
H1299 cells and examined the therapeutic potential of
this approach. First, the short hairpin RNA (shRNA)
against FAK was subcloned into pSi4.1CMV-f1, thus form-
ing pSilencer4.1-siFAK (pSi4.1-siFAK) (Fig. 1A). Then, we
purified ssDNA from phagemid particles to analyze the
ratio of phagemids to helper phage genomes packaged in
the phagemid particles. The results indicated that almost
all the DNA packaged comprised phagemids (Fig. 1B).
Previously, the modified helper phage genome (plasmid)
M13EGFKO7CT was created to produce EGF-targeted
phagemid particles [8,10]. The M13EGFKO7CT plasmid
was used to package pSi4.1-siFAK phagemid particles, fol-
lowing which the phagemid particles displayed the EGF
ligand. In the immunocytochemical assay, we found that
H1299 cells showed a strong positive EGFR immunoreac-
tivity, while very light immunostaining was observed in
the U87 cells that were used as negative controls (Fig. 2A).
Therefore, we infected H1299 cells with pSi4.1-siFAK
The map of pSi4.1-siFAK phagemid particle and analysis of the ssDNA released from phagemid particles Figure 1
The map of pSi4.1-siFAK phagemid particle and analysis of the ssDNA released from phagemid particles. A: 
pSi4.1-siFAK phagemid particle was constructed as follows: the shRNA against FAK was inserted into the modified pSilencer4.1 
vector digested with BamHI and HindIII. B: ssDNA was purified from phagemid particles to analyze the ratio of phagemids to 
helper phage genomes packaged in the phagemid particles. The results indicated that almost all the DNA packaged comprised 
phagemids. Lane M: λ DNA/HindIII; Lane 1: pSi4.1-siFAK phagemid particles; Lane 2: pSi4.1-simock phagemid particles.BMC Biotechnology 2008, 8:74 http://www.biomedcentral.com/1472-6750/8/74
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phagemid particles. Western blotting assay showed that
the pSi4.1-siFAK plasmid transfected by lipofectamine
could significantly block the expression of FAK. This was
not observed in cells transduced with pSi4.1-siFAK
phagemid particles without HCPT treatment. Surpris-
ingly, in HCPT treated-cells, the pSi4.1-siFAK phagemid
particles could inhibit FAK expression to a great extent.
Inhibition of FAK expression was not found in the cells
infected with mock phagemid particles (Fig. 2B). Taken
together, the vectors could deliver siRNA to human carci-
noma cells efficiently in the presence of HCPT. HCPT had
been shown to increase the efficiency of transduction of
the phagemid vectors [1,9,16]. However, the mechanism
by which HCPT increased transgene expression was not
fully understood [1,9]. It was thought to involve the acti-
vation of the host cell repair machinery in response to
DNA damage [1,16,17]; however, further studies are
required to confirm this.
A series of experiments were performed to determine
whether the pSi4.1-siFAK phagemid particles could arrest
H1299 cell growth. Cell growth was monitored by the
MTT assay, and it was observed that all the cells grew at a
similar rate at 0 and 24 h. However, a great difference
began to appear at 48 and 72 h. In the presence of HCPT,
the inhibitory rates were approximately 12–19% in parent
and mock cells, compared with parent cells without
HCPT. Amazingly, the inhibitory rates reached approxi-
mately 52–61% in HCPT-treated cells infected with
pSi4.1-siFAK phagemid particles, compared with the con-
trol cells. No significant growth inhibition was found in
the cells infected with the mock vector or pSi4.1-siFAK
phagemid particles in the absence of HCPT (Fig. 3A). In
addition, we examined the growth arrest of the pSi4.1-
siFAK phagemid particles at the 3-dimensional level. In
the colony-forming ability assay, the number of colonies
of pSi4.1-siFAK phagemid particles decreased by almost
Immunocytochemistry assay of EGFR expression and Western-blot analysis of the specific FAK gene silencing by EGF-targeted  phagemid particles mediated RNA interference Figure 2
Immunocytochemistry assay of EGFR expression and Western-blot analysis of the specific FAK gene silencing 
by EGF-targeted phagemid particles mediated RNA interference. A: In the immunocytochemical assay, H1299 cells 
showed a strong positive EGFR immunoreactivity, while very light immunostaining was observed in the U87 cells that were 
used as negative controls. 1, H1299; 2, U87. B: H1299 cells were infected with pSi4.1-siFAK phagemid particles. In HCPT 
treated-cells, the pSi4.1-siFAK phagemid particles could inhibit FAK expression to a great extent. 1, H1299; 2, H1299 infected 
with pSi4.1-simock phagemid particles; 3, H1299 infected with pSi4.1-simock phagemid particles in the presence of 2.5 μM 
HCPT; 4, H1299 infected with pSi4.1-siFAK phagemid particles; 5, H1299 infected with pSi4.1-siFAK phagemid particles in the 
presence of 2.5 μM HCPT; 6, H1299 transfected with pSi4.1-siFAK using Lipofectamine 2000.BMC Biotechnology 2008, 8:74 http://www.biomedcentral.com/1472-6750/8/74
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54% in the presence of HCPT, compared with the control
cells. In contrast, cells in other groups exhibited little
change in the number of colonies (Fig. 3B). These data
suggested that the treatment of pSi4.1-siFAK phagemid
particles could dramatically reduce cell viability in the
presence of HCPT.
Furthermore, we quantified the effect of pSi4.1-siFAK
phagemid particles on cell invasion. In the transwell inva-
sion assay, the number of pSi4.1-siFAK phagemid parti-
cles transduced-cells (HCPT treatment) invading through
the membrane coated with ECM gel was less than that of
the control cells (Fig. 4A). The cell invasion was markedly
reduced by approximately 50% in pSi4.1-siFAK phagemid
particles transduced-cells (HCPT treatment), compared
with the control cells; the other groups however showed
no obvious change (Fig. 4B). Thus, the above data indi-
cated that the transfection of H1299 cells with pSi4.1-
siFAK phagemid particles and the HCPT treatment could
dramatically inhibit cell invasion.
RNAi has revolutionized the biological sciences because it
can selectively silence messenger RNA (mRNA) expres-
sion. However, the delivery of this RNA into target cells
represents the main barrier for using siRNA as a novel
drug against tumor targets. Since filamentous phages only
showed tropism for cells that expressed the appropriate
receptors, this tropism could be conferred to phage parti-
cles by the expression of a targeting ligand on the phage
coat [3,4,6]. Therefore, phages would be an attractive
alternative strategy for siRNA delivery. This study demon-
strated that EGF-targeted phagemid particles in combina-
tion with RNAi and the HCPT treatment represent a new
therapeutic approach for silencing oncogenes. However,
in order to act as a cancer gene-delivery vector, phage vec-
tors should display other targeting ligands to increase
their specificity for different types of tumors.
Conclusion
Therefore, phages would be an attractive alternative strat-
egy for siRNA delivery. This study demonstrated that EGF-
targeted phagemid particles in combination with RNAi
and the HCPT treatment represent a new therapeutic
approach for silencing oncogenes. However, in order to
act as a cancer gene-delivery vector, phage vectors should
display other targeting ligands to increase their specificity
for different types of tumors.
Methods
Reagents
Dulbecco's Modified Eagle's Medium (DMEM), Dul-
becco's phosphate-buffered saline and fetal bovine serum
(FBS) were obtained from Invitrogen (Grand Island,
USA). Restriction endonucleases were obtained from
TaKaRa Biotechnology (Dalian, China).
Cell culture
H1299 (human lung carcinomas) cells and U87 (human
glioblastoma) cells were cultured at 37°C in DMEM con-
taining 10% FBS in a humidified atmosphere containing
5% CO2.
Plasmid construction
The modified pSilencer4.1 plasmid was obtained from
Dr. Z. Li (Shanghai Jiao Tong University, Shanghai,
China). FAK siRNA (target sequence, 5'-GAACCTCG-
CAGTCATTTAT-3') has been proven to be effective for
inhibiting FAK [18]. A 59-nt oligo-DNA duplex (5'-
AGCTTGAACCTCGCAGTCATTTATTTCAAGA-
GAATAAATGACTGCGAG GTTCTTTTTTG-3'/5'-
GATCCAAAAAAGAACCTCGCAGTCATTTATTCTCTTG
AAATAAATGACTGCGAGGTTCA-3') was inserted into the
pSilencer4.1 vector digested with BamHI and HindIII. The
mock siRNA sequence is 5'-GTCTCCGAACGTGTCACGT-
3' [18]. Another 59-nt oligo-DNA duplex (5'-
AGCTTGTCTCCGAACGTGTCACGTTTCAAGAGAACGT-
GACACGTTCGGAGACTTTTTTG-3'/5'-
GATCCAAAAAAGTCTCCGAACGTGTCACGTTCTCTT-
Phagemid particles of pSi4.1-siFAK could inhibit H1299 cell  growth Figure 3
Phagemid particles of pSi4.1-siFAK could inhibit 
H1299 cell growth. A: MTT assay. B: Colony-Forming Abil-
ity Assay. The results shown were representative of at least 
three independent experiments. The HCPT-treated cells that 
were infected with pSi4.1-siFAK phagemid particles exhibited 
a significant inhibition of proliferation (*, p < 0.01) compared 
with H1299 cells.BMC Biotechnology 2008, 8:74 http://www.biomedcentral.com/1472-6750/8/74
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GAAACGTGACACGTTCGGAGACA-3') was inserted into
the modified pSilencer4.1 vector digested with BamHI
and HindIII.
Preparation of phagemid particles
Briefly, M13KO7EGFCT was transformed into Escherichia
coli to create LMP cells [8]. The phagemid carrying siFAK
was transformed into the LMP cells. The cells were then
plated on Luria-Bertani (LB) agar containing 70 μg/mL
kanamycin and 50 μg/mL ampicillin and incubated at
37°C overnight. A cell clone was picked up and trans-
ferred into 1 L of LB solution containing 70 μg/mL kan-
amycin and 50 μg/mL ampicillin. After shaking at 37°C
for 15 h, the supernatant of the culture was collected and
the phagemid particles were purified with polyethylene
glycol (PEG)/NaCl precipitation. Then, they were quanti-
fied by ELISA as previously described [19].
Purification of single-stranded DNA from phagemid 
particles
Single-stranded DNA (ssDNA) was extracted from the
phagemid particles by using the Ph.D.-12 phage display
peptide library kit (New England Biolabs, USA) according
to the manufacturer's protocol. Briefly, the phagemid par-
Phagemid particles of pSi4.1-siFAK could inhibit H1299 cell invasion Figure 4
Phagemid particles of pSi4.1-siFAK could inhibit H1299 cell invasion. A: Cells that invaded after 36 hr through ECM-
Gel-coated transwell inserts were stained with crystal violet stain. B: Cell invasion assay. The HCPT-treated cells that were 
infected with pSi4.1-siFAK phagemid particles exhibited a significant inhibition of invasion (*, p < 0.01) compared with H1299 
cells.BMC Biotechnology 2008, 8:74 http://www.biomedcentral.com/1472-6750/8/74
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ticles were precipitated by PEG/NaCl. The pellet was then
suspended in iodide buffer. Ethanol (250 ml in total) was
added to the buffer, and the pellet was incubated in it for
10 min. The pellet was collected after centrifugation at 12
000 × g for 10 min. It was finally dissolved in 30 μL Tris-
EDTA (TE) buffer (10 mM Tris-HCl [pH 8.0] and 1 mM
EDTA) and analyzed by agarose gel electrophoresis.
Immunocytochemistry
Monolayer cells were grown on glass cover slips and fixed
with 4% paraformaldehyde. Endogenous peroxidase
activity was quenched with 2% hydrogen peroxide in
methanol for 45 min. After the cells were blocked with 5%
normal serum for 30 min, they were incubated with pri-
mary antibodies to the epidermal growth factor receptor
(EGFR) (Cell Signaling Technology, MA) diluted to 1:500
in phosphate-buffered saline (PBS) for 1 h at room tem-
perature. Then, the cells were rinsed and incubated with
horseradish peroxidase (HRP)-conjugated secondary anti-
bodies (Watson Biotech, China) diluted to 1:500 in PBS
for 1.5 h at room temperature. The reaction was devel-
oped with diaminobenzidine (Dako, Japan), and then the
slides were counterstained with Mayer's hematoxylin.
After a final wash, the slides were mounted and the cells
were examined using an Olympus photomicroscope
(400× magnification).
In vitro phagemid particle transfection
The cells were plated onto 24-well plates at a density of 10
000 cells per well 24 h prior to the addition of phage par-
ticles. The phages were added at 1011 pfu/mL and incu-
bated with the cells for 48 h at 37°C in complete media.
Then, the medium was removed and the cells were incu-
bated in fresh medium containing 2.5 μM HCPT for 6 h at
37°C. Following this, the medium was replaced with fresh
medium, and the cells were incubated for 18 h at 37°C.
All the transfections were performed in triplicate at least 2
times.
Western blot analysis
In total, 106 H1299 cells transfected with a variety of
phagemid particles were lysed after the HCPT treatment.
The cells were washed with PBS and lysed in a buffer con-
taining 50 mM Tris (pH 7.5), 5 mM EDTA, 300 mM NaCl,
0.1% Igepal, 0.5 mM NaF, 0.5 mM Na3VO4, 0.5 mM phe-
nylmethylsulfonyl fluoride, and an antiprotease mixture.
Equal amounts of protein were loaded on a SDS-PAGE
and transferred onto a nitrocellulose membrane. They
were incubated with specific primary antibodies and then
with HRP-conjugated secondary antibodies. Proteins were
visualized by fluorography using an enhanced chemilu-
minescence system (Pierce Biotechnologies, USA). The
anti-FAK antibody (Santa Cruz, CA) was used in 1:1000
dilutions. The monoclonal antibody to GAPDH was pur-
chased from Kang-Chen Biotech (Shanghai, China). The
secondary antibody conjugated with HRP was purchased
from Watson Biotech (Shanghai, China).
MTT assay
After the HCPT treatment, H1299 cells transfected with a
variety of phagemid particles were seeded onto a 96-well
plate overnight in DMEM containing 10% FBS, and then
grown for 0, 24, 48, and 72 h. Methyl thiazolyl tetrazo-
lium (MTT) (20 μL )  s o l u t i o n  ( 5  m g / m L  i n  P B S )  w a s
added to each well and incubated for 5 h at 37°C. The
solution was removed and 200 μL of dimethylsulfoxide
(DMSO) was added to each well. These plates were
vibrated gently for 10 min; they then underwent detection
in the universal microplate reader at 490 nm.
Colony-forming ability assay
The efficiency of colony formation was assayed in 35-mm
dishes prepared with a lower layer of 0.8% agar (GIBCO/
BRL) overlaid with 0.3% agar containing 2 × 104 sus-
pended cells. After 5 days, growth was estimated under a
Nikon inverted phase-contrast microscope, and individ-
ual colonies of more than 50 cells were counted [20].
Transwell invasion assay
Polymerized gels were prepared by neutralization of extra-
cellular matrix (ECM) gel (Sigma, USA) with cold DMEM.
Cells in DMEM with 0.5% bovine serum albumin (BSA)
were plated on the gel, and DMEM with 0.5% BSA and
0.5% FBS was added to the bottom of the chambers. Pho-
tographs were taken 36 h later to capture the cells that had
invaded below the gel surface. The number of invading
cells in 5 fields was counted under a 200× magnification.
Each value represents the average of 3 individual experi-
ments, and the error bars represent SD. p-values were cal-
culated by the ANOVA test in SAS8.2 [21].
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